Raffaella Buzzetti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7894508/publications.pdf

Version: 2024-02-01

232 papers

9,917 citations

53 h-index 53065

g-index

258 all docs

258 docs citations

258 times ranked

11580 citing authors

#	Article	IF	Citations
1	Underestimation of hypoglycaemia using patients' diaries compared with downloaded glucometer data: an <scp>ITAS</scp> post hoc analysis. Diabetes, Obesity and Metabolism, 2022, 24, 327-331.	2.2	2
2	SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness. American Journal of Cardiovascular Drugs, 2022, 22, 263-270.	1.0	7
3	The use of flash glucose monitoring significantly improves glycemic control in type 2 diabetes managed with basal bolus insulin therapy compared to self-monitoring of blood glucose: A prospective observational cohort study. Diabetes Research and Clinical Practice, 2022, 183, 109172.	1.1	5
4	Pathogenic variants of MODY-genes in adult patients with early-onset type 2 diabetes. Acta Diabetologica, 2022, , $1\cdot$	1.2	1
5	Development of a clinical risk score to predict death in patients with COVIDâ€19. Diabetes/Metabolism Research and Reviews, 2022, 38, e3526.	1.7	10
6	Association Between Platelet Reactivity and Long-Term Bleeding Complications After Percutaneous Coronary Intervention According to Diabetes Status. American Journal of Cardiology, 2022, 171, 49-54.	0.7	1
7	Third dose of COVIDâ€19 vaccine in diabetes: Relevance of good metabolic control to improve its efficacy. Diabetes/Metabolism Research and Reviews, 2022, 38, e3533.	1.7	4
8	Gender-sex differences in autoimmune atrophic gastritis. Translational Research, 2022, 248, 1-10.	2.2	7
9	Contribution of rare variants in monogenic diabetes-genes to early-onset type 2 diabetes. Diabetes and Metabolism, 2022, 48, 101353.	1.4	3
10	Corneal confocal microscopy identifies small nerve fibre damage in patients with hypertriglyceridemia. Journal of Clinical Lipidology, 2022, 16, 463-471.	0.6	4
11	Diastolic Pressure and ACR Are Modifiable Risk Factors of Arterial Stiffness in T2DM Without Cardiovascular Disease. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3857-e3865.	1.8	1
12	Câ€peptide determination in the diagnosis of type of diabetes and its management: A clinical perspective. Diabetes, Obesity and Metabolism, 2022, 24, 1912-1926.	2.2	34
13	Comparative effectiveness of Glargine 300 U/mL vs. Degludec 100 U/mL in patients with type 2 diabetes switching from $1\hat{A}^{\circ}$ generation basal insulins. Nutrition, Metabolism and Cardiovascular Diseases, 2022, , .	1.1	1
14	Vergleich der Wirksamkeit von Insulin glargin 300 E/ml (Gla-300) und Insulin degludec 100 E/ml (IDeg-100) bei insulin-naiven Erwachsenen mit Typ-2-Diabetes (T2D): Die RESTORE-2-Studie. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0
15	Differential involvement of myelinated and unmyelinated nerve fibers in painful diabetic polyneuropathy. Muscle and Nerve, 2021, 63, 68-74.	1.0	11
16	Risk of cardiac autonomic neuropathy in latent autoimmune diabetes in adults is similar to type 1 diabetes and lower compared to type 2 diabetes: A crossâ€sectional study. Diabetic Medicine, 2021, 38, e14455.	1.2	7
17	Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths. Diabetes Research and Clinical Practice, 2021, 171, 108444.	1.1	23
18	Similar glycaemic control and risk of hypoglycaemia with patient- versus physician-managed titration of insulin glargine 300 U/mL across subgroups of patients with T2DM: a post hoc analysis of ITAS. Acta Diabetologica, 2021, 58, 789-796.	1.2	0

#	Article	IF	Citations
19	Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24Âmonths follow-up study. Diabetes Research and Clinical Practice, 2021, 173, 108681.	1.1	8
20	Effects of the <scp>COVID</scp> â€19 lockdown on glycaemic control in subjects with type 2 diabetes: the glycalock study. Diabetes, Obesity and Metabolism, 2021, 23, 1624-1630.	2.2	41
21	The complex combination of COVID-19 and diabetes: pleiotropic changes in glucose metabolism. Endocrine, 2021, 72, 317-325.	1.1	29
22	Association of bone biomarkers with advanced atherosclerotic disease in people with overweight/obesity. Endocrine, 2021, 73, 339-346.	1.1	8
23	Small Nerve Fiber Damage and Langerhans Cells in Type 1 and Type 2 Diabetes and LADA Measured by Corneal Confocal Microscopy., 2021, 62, 5.		17
24	Weltweite regionale Unterschiede bei Blutzuckereinstellung, HypoglykÃ#nieraten und Krankheitsmanagement bei Erwachsenen mit Diabetes mellitus Typ 1 (T1DM): Die SAGE-Studie. , 2021, 16, .		0
25	Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 103.	2.7	3
26	Impact of cardiovascular disease on clinical outcomes in hospitalized patients with Covid-19: a systematic review and meta-analysis. Internal and Emergency Medicine, 2021, 16, 1975-1985.	1.0	6
27	Improving clinical utility of GAD65 autoantibodies by electrochemiluminescence assay and clinical phenotype when identifying autoimmune adult-onset diabetes. Diabetologia, 2021, 64, 2052-2060.	2.9	11
28	Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes. Diabetes Research and Clinical Practice, 2021, 179, 109022.	1.1	15
29	Adult-Onset Type 1 Diabetes: Current Understanding and Challenges. Diabetes Care, 2021, 44, 2449-2456.	4.3	73
30	Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes. Expert Opinion on Investigational Drugs, 2021, 30, 1209-1219.	1.9	14
31	Osteocalcin and sclerostin: Background characters or main actors in cardiovascular disease?. Diabetes/Metabolism Research and Reviews, 2020, 36, e3217.	1.7	10
32	Wrist circumference is a biomarker of adipose tissue dysfunction and cardiovascular risk in children with obesity. Journal of Endocrinological Investigation, 2020, 43, 101-107.	1.8	17
33	Pasta Consumption and Connected Dietary Habits: Associations with Glucose Control, Adiposity Measures, and Cardiovascular Risk Factors in People with Type 2 Diabetes—TOSCA.IT Study. Nutrients, 2020, 12, 101.	1.7	17
34	Clinical features of patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I). Diabetes Research and Clinical Practice, 2020, 169, 108454.	1.1	32
35	Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel. Diabetes, 2020, 69, 2037-2047.	0.3	129
36	Adult-onset autoimmune diabetes in 2020: An update. Maturitas, 2020, 137, 37-44.	1.0	27

#	Article	IF	Citations
37	Effects of COVID-19 Lockdown on Glucose Control: Continuous Glucose Monitoring Data From People With Diabetes on Intensive Insulin Therapy. Diabetes Care, 2020, 43, e86-e87.	4.3	67
38	Covidâ€19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes/Metabolism Research and Reviews, 2020, 36, e33213321.	1.7	228
39	Impact of obesity on the increasing incidence of type 1 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1009-1013.	2.2	28
40	The Vicious Circle of Left Ventricular Dysfunction and Diabetes: From Pathophysiology to Emerging Treatments. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3075-e3089.	1.8	11
41	Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86). Lancet Diabetes and Endocrinology, the, 2020, 8, 206-215.	5.5	36
42	Comparable efficacy with similarly low risk of hypoglycaemia in patient―vs physicianâ€managed basal insulin initiation and titration in insulinâ€naÃ⁻ve type 2 diabetic subjects: The Italian Titration Approach Study. Diabetes/Metabolism Research and Reviews, 2020, 36, e3304.	1.7	11
43	Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II). Cardiovascular Diabetology, 2020, 19, 164.	2.7	90
44	Association of OPG–RANKL ratio with left ventricular hypertrophy and geometric remodeling in male overweight/obese youths. Journal of Endocrinological Investigation, 2019, 42, 427-434.	1.8	5
45	Sclerostin is expressed in the atherosclerotic plaques of patients who undergoing carotid endarterectomy. Diabetes/Metabolism Research and Reviews, 2019, 35, e3069.	1.7	25
46	Risk factors and predictive biomarkers of early cardiovascular disease in obese youth. Diabetes/Metabolism Research and Reviews, 2019, 35, e3134.	1.7	31
47	Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents. Diabetes Therapy, 2019, 10, 1113-1125.	1.2	8
48	Similar effectiveness of dapagliflozin and GLPâ€1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospective study. Diabetes, Obesity and Metabolism, 2019, 21, 1886-1894.	2.2	17
49	Italian Titration Approach Study (ITAS) with insulin glargine 300ÂU/mL in insulin-naÃ-ve type 2 diabetes: Design and population. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 496-503.	1.1	7
50	Why only macro and not micro in type 2 diabetes? Time to change the goals of clinical trials in diabetes. Diabetes/Metabolism Research and Reviews, 2018, 34, e3012.	1.7	3
51	Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics. Diabetes, Obesity and Metabolism, 2018, 20, 2014-2018.	2.2	26
52	Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A <i>postâ€hoc</i> analysis of the AWARDâ€2, â€4 and â€5 Trials. Diabetes, Obesity and Metabolism, 2 20, 1490-1498.	01282	40
53	Wrist circumference is associated with increased systolic blood pressure in children with overweight/obesity. Hypertension Research, 2018, 41, 193-197.	1.5	11
54	Metabolic control and complications in Italian people with diabetes treated with continuous subcutaneous insulin infusion. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 335-342.	1.1	8

#	Article	IF	CITATIONS
55	Serum Sclerostin and Bone Turnover in Latent Autoimmune Diabetes in Adults. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1921-1928.	1.8	34
56	Relation Between Wrist Circumference and Left Ventricular Structure in Overweight Children. American Journal of Cardiology, 2018, 121, 1624-1628.	0.7	9
57	Variability in genes regulating vitamin D metabolism is associated with vitamin D levels in type 2 diabetes. Oncotarget, 2018, 9, 34911-34918.	0.8	5
58	Response to the comment on: "Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A postâ€hoc analysis of the AWARDâ€2, â€4 and â€5 trials― Diabetes, Obesity and Metabolism, 2018, 20, 2319-2320.	2.2	О
59	SP439EVALUATION OF VASCULAR DAMAGE BY CARDIO-ANKLE VASCULAR INDEX (CAVI) IN TYPE 2 DIABETES PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i496-i496.	0.4	1
60	LADA. Endocrinology, 2018, , 1-43.	0.1	0
61	Evidence of diabetesâ€specific autoimmunity in obese subjects with normal glucose tolerance. Diabetes/Metabolism Research and Reviews, 2018, 34, e3055.	1.7	10
62	Impact of a Mediterranean Dietary Pattern and Its Components on Cardiovascular Risk Factors, Glucose Control, and Body Weight in People with Type 2 Diabetes: A Real-Life Study. Nutrients, 2018, 10, 1067.	1.7	92
63	LADA. Endocrinology, 2018, , 255-297.	0.1	1
64	The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3. PLoS ONE, 2018, 13, e0190579.	1.1	2
65	A multistep approach for the stratification of the risk of severe hypoglycemia in patients with type 2 diabetes. Minerva Endocrinology, 2018, 43, 501-510.	0.6	7
66	Reduction of HbA1c with dulaglutide in type 2 diabetes (T2D) patients negative, low positive or high positive for GAD antibodies (GADA): a post hoc analysis of AWARD -2, -4 and -5. Diabetologie Und Stoffwechsel, 2018, 13, .	0.0	0
67	Vitamin K and osteoporosis: Myth or reality?. Metabolism: Clinical and Experimental, 2017, 70, 57-71.	1.5	103
68	Pathophysiology of Bone Fragility in Patients with Diabetes. Calcified Tissue International, 2017, 100, 122-132.	1.5	71
69	Interleukin-18 mediates cardiac dysfunction induced by western diet independent of obesity and hyperglycemia in the mouse. Nutrition and Diabetes, 2017, 7, e258-e258.	1.5	27
70	Dietary Fat, Sugar Consumption, andÂCardiorespiratoryÂFitness in PatientsÂWithÂHeartÂFailureÂWith PreservedÂEjectionÂFraction. JACC Basic To Translational Science, 2017, 2, 513-525.	1.9	51
71	Rationale and design of the DARWIN-T2D (DApagliflozin Real World evideNce in Type 2 Diabetes). Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 1089-1097.	1.1	26
72	Adult-onset autoimmune diabetes: current knowledge and implications for management. Nature Reviews Endocrinology, 2017, 13, 674-686.	4.3	187

#	Article	IF	Citations
73	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 887-897.	5.5	231
74	High prevalence of diabetesâ€specific autoimmunity in firstâ€degree relatives of Sardinian patients with type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2017, 33, e2864.	1.7	9
75	Clinical worthlessness of genetic prediction of common forms of diabetes mellitus and related chronic complications. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 99-114.	1.1	10
76	Polyphenol intake and cardiovascular risk factors in a population with Atype 2 diabetes: The TOSCA.IT study. Clinical Nutrition, 2017, 36, 1686-1692.	2.3	52
77	ISA-2011B, a Phosphatidylinositol 4-Phosphate 5-Kinase α Inhibitor, Impairs CD28-Dependent Costimulatory and Pro-inflammatory Signals in Human T Lymphocytes. Frontiers in Immunology, 2017, 8, 502.	2.2	22
78	Sex differences in food choices, adherence to dietary recommendations and plasma lipid profile in type 2 diabetes – The TOSCA.IT study. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 879-885.	1.1	43
79	Position <scp>S</scp> tatement on the management of continuous subcutaneous insulin infusion (<scp>CSII</scp>): The Italian Lazio experience. Journal of Diabetes, 2016, 8, 41-44.	0.8	2
80	Obesity Contributes to Exercise Intolerance in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2016, 68, 2487-2488.	1.2	56
81	Saxagliptin improves glycaemic control and Câ€peptide secretion in latent autoimmune diabetes in adults (LADA). Diabetes/Metabolism Research and Reviews, 2016, 32, 289-296.	1.7	54
82	Relation of Body Circumferences to Cardiometabolic Disease in Overweight-Obese Subjects. American Journal of Cardiology, 2016, 118, 822-827.	0.7	20
83	The "Sapienza University Mortality and Morbidity Event Rate (SUMMER) study in diabetes― Study protocol. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 103-108.	1.1	5
84	Exercise at lunchtime: effect on glycemic control and oxidative stress in middle-aged men with type 2 diabetes. European Journal of Applied Physiology, 2016, 116, 573-582.	1.2	34
85	Influence of dietary fat and carbohydrates proportions on plasma lipids, glucose control and low-grade inflammation in patients with type 2 diabetesâ€"The TOSCA.IT Study. European Journal of Nutrition, 2016, 55, 1645-1651.	1.8	42
86	Excellent Intra and Inter-Observer Reproducibility of Wrist Circumference Measurements in Obese Children and Adolescents. PLoS ONE, 2016, 11, e0156646.	1.1	12
87	Latent Autoimmune Diabetes in Adults in the United Arab Emirates: Clinical Features and Factors Related to Insulin-Requirement. PLoS ONE, 2015, 10, e0131837.	1.1	68
88	Detection of Insulitis by Pancreatic Scintigraphy With 99mTc-Labeled IL-2 and MRI in Patients With LADA (Action LADA 10). Diabetes Care, 2015, 38, 652-658.	4.3	35
89	Tyrosine Phosphataseâ€"Related Islet Antigen 2(256â€"760) Autoantibodies, the Only Marker of Islet Autoimmunity That Increases by Increasing the Degree of BMI in Obese Subjects With Type 2 Diabetes. Diabetes Care, 2015, 38, 513-520.	4.3	29
90	Continuous Subcutaneous Insulin Infusion in Italy: Third National Survey. Diabetes Technology and Therapeutics, 2015, 17, 96-104.	2.4	18

#	Article	IF	CITATIONS
91	Combination immunotherapies for type 1 diabetes mellitus. Nature Reviews Endocrinology, 2015, 11, 289-297.	4.3	72
92	A high-sugar and high-fat diet impairs cardiac systolic and diastolic function in mice. International Journal of Cardiology, 2015, 198, 66-69.	0.8	61
93	The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care. Journal of Diabetes and Its Complications, 2015, 29, 599-606.	1.2	17
94	Adult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype: Action LADA 7. Diabetes Care 2013;36:908–913. Diabetes Care, 2014, 37, 1494-1494.	4.3	o
95	Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. Nephrology Dialysis Transplantation, 2014, 29, 657-662.	0.4	49
96	High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD) Tj ETQq0 C	0 0 <u>f</u> gBT /C	overlock 10 Tf
97	Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes according to different classification systems for chronic kidney disease: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovascular Diabetology, 2014, 13, 59.	2.7	24
98	Chronic kidney disease in type 2 diabetes: Lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 815-822.	1.1	51
99	Prevention of type 2 diabetes mellitus: is it feasible?. Diabetes/Metabolism Research and Reviews, 2014, 30, 4-12.	1.7	34
100	HLA-dependent autoantibodies against post-translationally modified collagen type II in type 1 diabetes mellitus. Diabetologia, 2013, 56, 563-572.	2.9	34
101	HbA1c Variability as an Independent Correlate of Nephropathy, but Not Retinopathy, in Patients With Type 2 Diabetes. Diabetes Care, 2013, 36, 2301-2310.	4.3	130
102	Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the <scp>RIACE</scp> Italian multicentre study. Journal of Internal Medicine, 2013, 274, 176-191.	2.7	111
103	Epigenetics in autoimmune diseases with focus on type 1 diabetes. Diabetes/Metabolism Research and Reviews, $2013, 29, 8-18$.	1.7	72
104	The METABOLIC Study: Multidimensional assessment of health and functional status in older patients with type 2 diabetes taking oral antidiabetic treatment. Diabetes and Metabolism, 2013, 39, 236-243.	1.4	14
105	Latent autoimmune diabetes in adults is perched between type 1 and type 2: evidence from adults in one region of Spain. Diabetes/Metabolism Research and Reviews, 2013, 29, 446-451.	1.7	49
106	Adult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype. Diabetes Care, 2013, 36, 908-913.	4.3	253
107	A stochastic mathematical model to study the autoimmune progression towards type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2013, 29, 194-203.	1.7	8
108	Immunotherapy for T1DMâ€"still not there yet. Nature Reviews Endocrinology, 2013, 9, 697-698.	4.3	3

#	Article	IF	CITATIONS
109	Assessment of Type 1 Diabetes Risk Conferred by HLA-DRB1, INS-VNTR and PTPN22 Genes Using the Bayesian Network Approach. PLoS ONE, 2013, 8, e79506.	1.1	6
110	Effect of Calcitriol on Bone Turnover and Osteocalcin in Recent-Onset Type 1 Diabetes. PLoS ONE, 2013, 8, e56488.	1.1	20
111	Temporal Trends of HLA, CTLA-4 and PTPN22 Genotype Frequencies among Type 1 Diabetes in Continental Italy. PLoS ONE, 2013, 8, e61331.	1.1	3
112	Diabetes-Related Autoantibodies in Children With Acute Lymphoblastic Leukemia. Diabetes Care, 2012, 35, e23-e23.	4.3	2
113	Diabete autoimmune dell'adulto (LADA): diagnosi e terapia. L Endocrinologo, 2012, 13, 264-269.	0.0	0
114	GADA Titer-Related Risk for Organ-Specific Autoimmunity in LADA Subjects Subdivided according to Gender (NIRAD Study 6). Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3759-3765.	1.8	62
115	Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature, 2012, 483, 350-354.	13.7	572
116	High prevalence of advanced retinopathy in patients with type 2 diabetes from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. Diabetes Research and Clinical Practice, 2012, 98, 329-337.	1.1	29
117	Increased serum concentrations of adhesion molecules but not of chemokines in patients with Type $\hat{a} \in f2$ diabetes compared with patients with Type $\hat{a} \in f1$ diabetes and latent autoimmune diabetes in adult age: Action LADA $\hat{a} \in f5$. Diabetic Medicine, 2012, 29, 470-478.	1.2	37
118	Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. Journal of Hypertension, 2011, 29, 1802-1809.	0.3	198
119	C-Peptide Response and HLA Genotypes in Subjects With Recent-Onset Type 1 Diabetes After Immunotherapy With DiaPep277. Diabetes, 2011, 60, 3067-3072.	0.3	40
120	Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4. Diabetologia, 2011, 54, 1630-1638.	2.9	89
121	Blue eyes as a risk factor for type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2011, 27, 609-613.	1.7	16
122	Recognition of Ii-Key/MHC Class II Epitope Hybrids Derived from Proinsulin and GAD Peptides by T Cells in Type 1 Diabetes. Hormone and Metabolic Research, 2011, 43, 483-488.	0.7	2
123	Clinical Update on the Use of Immuno Modulators (antiCD3, GAD, Diapep277, Anti-IL1) in Type 1 Diabetes. Current Pharmaceutical Design, 2011, 17, 3224-3228.	0.9	12
124	Wrist Circumference Is a Clinical Marker of Insulin Resistance in Overweight and Obese Children and Adolescents. Circulation, 2011, 123, 1757-1762.	1.6	68
125	Obesity, Autoimmunity, and Double Diabetes in Youth. Diabetes Care, 2011, 34, S166-S170.	4. 3	65
126	Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia. Leukemia Research, 2010, 34, e5-e7.	0.4	14

#	Article	IF	CITATIONS
127	Association of <i>TCF7L2</i> gene variants with low GAD autoantibody titre in LADA subjects (NIRAD) Tj ETQq1 1	. 9.784314 1.2	f rgBT /Overl
128	Homozygosity for the Ala Allele of the PPARγ2 Pro12Ala Polymorphism Is Associated with Reduced Risk of Coronary Artery Disease. Disease Markers, 2010, 29, 259-264.	0.6	13
129	Zinc Transporter 8 Antibodies Complement GAD and IA-2 Antibodies in the Identification and Characterization of Adult-Onset Autoimmune Diabetes. Diabetes Care, 2010, 33, 104-108.	4.3	136
130	No Protective Effect of Calcitriol on \hat{I}^2 -Cell Function in Recent-Onset Type 1 Diabetes. Diabetes Care, 2010, 33, 1962-1963.	4.3	133
131	Incidence of Type 1 Diabetes Has Doubled in Rome and the Lazio Region in the 0- to 14-Year Age-Group: A 6-Year Prospective Study (2004-2009). Diabetes Care, 2010, 33, e140-e140.	4.3	8
132	Circulating Reg1 \hat{l} ± Proteins and Autoantibodies to Reg1 \hat{l} ± Proteins as Biomarkers of \hat{l} ² -Cell Regeneration and Damage in Type 1 Diabetes. Hormone and Metabolic Research, 2010, 42, 955-960.	0.7	21
133	HLA-DRB1*03 and DRB1*04 are associated with atrophic gastritis in an Italian population. Digestive and Liver Disease, 2010, 42, 854-859.	0.4	20
134	Homozygosity for the Ala allele of the PPARÎ ³ 2 Pro12Ala polymorphism is associated with reduced risk of coronary artery disease. Disease Markers, 2010, 29, 259-64.	0.6	10
135	Î ² -Cell Protection and Therapy for Latent Autoimmune Diabetes in Adults. Diabetes Care, 2009, 32, S246-S252.	4.3	42
136	Metabolic Syndrome and Autoimmune Diabetes: Action LADA 3. Diabetes Care, 2009, 32, 160-164.	4.3	104
137	The Q121 Variant of ENPP1 May Protect From Childhood Overweight/obesity in the Italian Population. Obesity, 2009, 17, 202-206.	1.5	7
138	Diabetes classification: grey zones, sound and smoke: Action LADA 1. Diabetes/Metabolism Research and Reviews, 2008, 24, 511-519.	1.7	115
139	A new variation in the promoter region, the â^'604 C>T, and the Leu72Met polymorphism of the ghrelin gene are associated with protection to insulin resistance. International Journal of Obesity, 2008, 32, 663-668.	1.6	37
140	A 10â€year (1996–2005) prospective study of the incidence of Type 1 diabetes in Moscow in the age group 0–14Âyears. Diabetic Medicine, 2008, 25, 956-959.	1.2	12
141	Type 1 diabetes risk for human leukocyte antigen (HLA)-DR3 haplotypes depends on genotypic context: Association of DPB1 and HLA class I loci among DR3- and DR4-matched Italian patients and controls. Human Immunology, 2008, 69, 291-300.	1.2	21
142	The Protein Tyrosine Phosphatase Nonreceptor 22 (<i>PTPN22</i>) Is Associated With High GAD Antibody Titer in Latent Autoimmune Diabetes in Adults. Diabetes Care, 2008, 31, 534-538.	4.3	56
143	The PTPN22 1858T Gene Variant in Type 1 Diabetes Is Associated With Reduced Residual \hat{A} -Cell Function and Worse Metabolic Control. Diabetes Care, 2008, 31, 1214-1218.	4.3	35
144	Identification of Sequence Variants in the UBL5 (Ubiquitin-like 5 or BEACON) Gene in Obese Children by PCR-SSCP: No Evidence for Association with Obesity. Journal of Pediatric Endocrinology and Metabolism, 2008, 21, 1139-45.	0.4	3

#	Article	IF	CITATIONS
145	Distinct Monocyte Gene-Expression Profiles in Autoimmune Diabetes. Diabetes, 2008, 57, 2768-2773.	0.3	68
146	Time to Insulin Initiation Cannot Be Used in Defining Latent Autoimmune Diabetes in Adults. Diabetes Care, 2008, 31, 439-441.	4.3	69
147	Identification of Tyrosine Phosphatase 2(256–760) Construct as a New, Sensitive Marker for the Detection of Islet Autoimmunity in Type 2 Diabetic Patients. Diabetes, 2008, 57, 1276-1283.	0.3	53
148	High Titer of Autoantibodies to GAD Identifies a Specific Phenotype of Adult-Onset Autoimmune Diabetes. Diabetes Care, 2007, 30, 932-938.	4.3	206
149	Evidence by allelic association-dependent methods for a type 1 diabetes polygene (IDDM6) on chromosome 18q21. Human Molecular Genetics, 2007, 16, 3197-3197.	1.4	0
150	Non-synonymous polymorphisms in melanocortin-4 receptor protect against obesity: the two facets of a Janus obesity gene. Human Molecular Genetics, 2007, 16, 1837-1844.	1.4	174
151	A new expression of diabetes: double diabetes. Trends in Endocrinology and Metabolism, 2007, 18, 52-57.	3.1	77
152	Aminotransferase activity in morbid and uncomplicated obesity: Predictive role of fasting insulin. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 442-447.	1.1	20
153	High Frequency of the TCRBV20S1 Null Allele in the Sardinian Population. Human Immunology, 2007, 68, 426-429.	1.2	4
154	The glucose clamp reveals an association between adiponectin gene polymorphisms and insulin sensitivity in obese subjects. International Journal of Obesity, 2007, 31, 424-428.	1.6	19
155	Relative predispositional effects of HLA class II DRB1-DQB1 haplotypes and genotypes on type 1 diabetes: a meta-analysis. Tissue Antigens, 2007, 70, 110-127.	1.0	153
156	Length of gestation and gender are associated with HLA genotypes at risk for TypeÂ1 diabetes (Italian) Tj ETQq0	0 0 rgBT /0 1.2	Overlock 10 1
157	Low-risk HLA genotype in TypeÂ1 diabetes is associated with less destruction of pancreatic B-cells 12Âmonths after diagnosis. Diabetic Medicine, 2007, 24, 1487-1490.	1.2	14
158	HLA class II distribution in Congolese with hyperthyroidism: preliminary results. Annales D'Endocrinologie, 2006, 67, 596-603.	0.6	0
159	The 3′-UTR C>T polymorphism of the oxidized LDL-receptor 1 (OLR1) gene does not associate with coronary artery disease in Italian CAD patients or with the severity of coronary disease. Nutrition, Metabolism and Cardiovascular Diseases, 2006, 16, 345-352.	1.1	28
160	Blood ketone bodies in patients with recent-onset type 1 diabetes (a multicenter study). Pediatric Diabetes, 2006, 7, 223-228.	1.2	29
161	The Promoter Region of the Adiponectin Gene Is a Determinant in Modulating Insulin Sensitivity in Childhood Obesity. Obesity, 2006, 14, 1498-1504.	1.5	53
162	Left Ventricular Mass and +276 G/G Single Nucleotide Polymorphism of the Adiponectin Gene in Uncomplicated Obesity*. Obesity, 2006, 14, 368-372.	1.5	16

#	Article	IF	CITATIONS
163	Association of \hat{l}^22 adrenergic receptor polymorphisms and related haplotypes with triglyceride and LDL-cholesterol levels. European Journal of Human Genetics, 2006, 14, 94-100.	1.4	23
164	Metabolic Factors Affecting Residual Beta Cell Function Assessed by C-Peptide Secretion in Patients with Newly Diagnosed Type 1 Diabetes. Hormone and Metabolic Research, 2006, 38, 668-672.	0.7	22
165	Residual insulin secretion at diagnosis of type 1 diabetes is independently associated with both, age of onset and HLA genotype. Diabetes/Metabolism Research and Reviews, 2005, 21, 271-275.	1.7	41
166	The Gly482Ser Missense Mutation of the Peroxisome Proliferator-Activated Receptor \hat{l}^3 Coactivator- $1\hat{l}\pm$ (PGC- $1\hat{l}\pm$) Gene Associates with Reduced Insulin Sensitivity in Normal and Glucose-Intolerant Obese Subjects. Disease Markers, 2005, 21, 175-180.	0.6	38
167	PPAR- \hat{I}^3 2 Pro12Ala Variant Is Associated with Greater Insulin Sensitivity in Childhood Obesity. Pediatric Research, 2005, 57, 138-140.	1.1	38
168	A Two Year Observational Study of Nicotinamide and Intensive Insulin Therapy in Patients with Recent Onset Type I Diabetes Mellitus. Journal of Pediatric Endocrinology and Metabolism, 2005, 18, 749-54.	0.4	40
169	CT60 Single Nucleotide Polymorphisms of the Cytotoxic T-Lymphocyte–Associated Antigen-4 Gene Region is Associated with Graves' Disease in an Italian Population. Thyroid, 2005, 15, 232-238.	2.4	59
170	Glucose evaluation trial for remission (GETREM) in type 1 diabetes: a European multicentre study. Diabetes Research and Clinical Practice, 2005, 68, 258-264.	1.1	34
171	Screening for type 1 diabetes genetic risk in newborns of continental Italy. Primary prevention (Prevefin Italy)preliminary data. Acta Biomedica, 2005, 76 Suppl 3, 31-5.	0.2	3
172	The common PPAR- $\hat{1}^3$ 2 Pro12Ala variant is associated with greater insulin sensitivity. European Journal of Human Genetics, 2004, 12, 1050-1054.	1.4	57
173	Genetic prediction of type 1 diabetes in a population with low frequency of HLA risk genotypes and low incidence of the disease(the DIABFIN study). Diabetes/Metabolism Research and Reviews, 2004, 20, 137-143.	1.7	29
174	HLA class II typing in newborns reveals a low frequency of the DRB1*04 allele and a high frequency of DRB1*11 allele in three regions of continental Italy. Human Immunology, 2004, 65, 366-372.	1.2	6
175	The Gly972->Arg IRS-1 Variant Is Associated With Type 1 Diabetes in Continental Italy. Diabetes, 2003, 52, 887-890.	0.3	36
176	IL12B Polymorphism and Type 1 Diabetes in the Italian Population: A Case-Control Study. Diabetes, 2002, 51, 1649-1650.	0.3	24
177	Quantification of the genetic component in multi-factorial autoimmune endocrinopathies. Journal of Endocrinological Investigation, 2002, 25, 751-752.	1.8	0
178	Genotypes of cytosolic low[ndash] molecular-weight protein-tyrosine-phosphatase correlate with age at onset of type 1 diabetes in a sex-specific manner. Metabolism: Clinical and Experimental, 2002, 51, 419-422.	1.5	26
179	Association of CTLA-4 variation with type I diabetes in Filipinos. Immunogenetics, 2002, 54, 310-313.	1.2	17
180	The association of specific HLA class I and II alleles with type 1 diabetes among Filipinos. Tissue Antigens, 2002, 59, 452-469.	1.0	62

#	Article	IF	CITATIONS
181	Similar incidence of type 1 diabetes in two ethnically different populations (Italy and Slovenia) is sustained by similar HLA susceptible/protective haplotype frequencies. Tissue Antigens, 2002, 60, 244-253.	1.0	28
182	Multiple sclerosis and Type I diabetes. Diabetologia, 2002, 45, 1735-1736.	2.9	9
183	Association of DRB1*04-DQB1*0301 Haplotype and Lack of Association of Two Polymorphic Sites at CTLA-4 Gene with Hashimoto's Thyroiditis in an Italian Population. Thyroid, 2001, 11, 171-175.	2.4	88
184	The G972R variant of the Insulin Receptor Substrate-1 (IRS-1) gene, body fat distribution and insulin-resistance. Diabetologia, 2001, 44, 367-372.	2.9	61
185	The distribution of HLA class II susceptible/protective haplotypes could partially explain the low incidence of type 1 diabetes in continental Italy (Lazio region). Tissue Antigens, 2001, 58, 385-394.	1.0	54
186	Suggestive Evidence for Association of Human Chromosome 18q12-q21 and Its Orthologue on Rat and Mouse Chromosome 18 With Several Autoimmune Diseases. Diabetes, 2001, 50, 184-194.	0.3	69
187	Autoantibody negative new onset Type 1 diabetic patients lacking high risk HLA alleles in a Caucasian population: are these Type 1b diabetes cases?. Diabetes/Metabolism Research and Reviews, 2000, 16, 8-14.	1.7	22
188	No effect of oral insulin on residual beta-cell function in recent-onset Type I diabetes (the IMDIAB VII). Diabetologia, 2000, 43, 1000-1004.	2.9	207
189	The dancer dwarf. Journal of Endocrinological Investigation, 2000, 23, 345-345.	1.8	1
190	Autoantibody negative new onset Type 1 diabetic patients lacking high risk HLA alleles in a Caucasian population: are these Type $1b$ diabetes cases?., 2000, 16 , 8 .		2
191	No evidence of association of chromosome 2 q with Type I diabetes in the Basque population. Diabetologia, 1999, 42, 119-120.	2.9	6
192	A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset Type 1 diabetes (the IMDIAB VI). Diabetes/Metabolism Research and Reviews, 1999, 15, 181-185.	1.7	40
193	CTLA-4 and HLA gene susceptibility to thyroidassociated orbitopathy. Lancet, The, 1999, 354, 1824.	6.3	33
194	Dissecting the genetics of Type 1 diabetes: relevance for familial clustering and differences in incidence., 1998, 14, 111-128.		49
195	High frequency of polymorphism but no mutations found in the GLUT1 glucose transporter gene in NIDDM and familial obesity by SSCP analysis. Human Genetics, 1998, 102, 479-482.	1.8	7
196	Metabolic and immune parameters at clinical onset of insulin-dependent diabetes: A population-based study. Metabolism: Clinical and Experimental, 1998, 47, 1205-1210.	1.5	61
197	Fine Mapping of the Diabetes-Susceptibility Locus, IDDM4, on Chromosome $11q13$. American Journal of Human Genetics, 1998, 63, 547-556.	2.6	56
198	Genetic analysis of chromosome 2 in type 1 diabetes: analysis of putative loci IDDM7, IDDM12, and IDDM13 and candidate genes NRAMP1 and IA-2 and the interleukin-1 gene cluster. IMDIAB Group. Diabetes, 1998, 47, 1797-1799.	0.3	66

#	Article	IF	Citations
199	Vitamin E and nicotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study). European Journal of Endocrinology, 1997, 137, 234-239.	1.9	49
200	Evidence by allelic association-dependent methods for a type 1 diabetes polygene (IDDM6) on chromosome 18q21. Human Molecular Genetics, 1997, 6, 1003-1010.	1.4	81
201	Insulin VNTR allele-specific effect in type 1 diabetes depends on identity of untransmitted paternal allele. Nature Genetics, 1997, 17, 350-352.	9.4	183
202	Non-HLA genes and the susceptibility to insulin dependent diabetes: the role of the CTLA-4 gene. Acta Diabetologica, 1996, 33, 250-252.	1.2	3
203	Confirmation of three susceptibility genes to insulin-dependent diabetes mellitus: IDDM4, IDDM5 and IDDM8. Human Molecular Genetics, 1996, 5, 693-698.	1.4	115
204	The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Human Molecular Genetics, 1996, 5, 1075-1080.	1.4	686
205	A 5-year (1989-1993) Prospective Study of the Incidence of IDDM in Rome and the Lazio Region in the Age-Group 0-14 years. Diabetes Care, 1996, 19, 70-73.	4.3	27
206	Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia, 1995, 38, 848-852.	2.9	68
207	Response from the authors. Diabetologia, 1995, 38, 126-126.	2.9	0
208	Linkage disequilibrium mapping of a type 1 diabetes susceptibility gene (IDDM7) to chromosome 2q31–q33. Nature Genetics, 1995, 9, 80-85.	9.4	226
209	New and old trends for treating organ-specific autoimmune endocrinopathies. Journal of Endocrinology, 1995, 145, 195-199.	1.2	0
210	Combination of Nicotinamide and Steroid Versus Nicotinamide in Recent-Onset IDDM: The IMDIAB II Study. Diabetes Care, 1994, 17, 897-900.	4.3	14
211	Selection of control subjects for case/control analysis of susceptibility to Type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 1994, 37, 845-846.	2.9	1
212	Randomized Trial Comparing Nicotinamide and Nicotinamide Plus Cyclosporin in Recent Onset Insulinâ€dependent Diabetes (IMDIAB 1). Diabetic Medicine, 1994, 11, 98-104.	1.2	34
213	Analysis of HLA-DQ Alpha and DQ Beta Genes in Type I (Insulin-dependent) Diabetes., 1994,, 181-185.		0
214	The selection of control subjects for case/control analysis of susceptibility to Type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 1993, 36, 1208-1209.	2.9	12
215	HLA-DQA1 and DQB1 Gene Polymorphisms in Type I Diabetic Patients from Central Italy and Their Use for Risk Prediction. Diabetes, 1993, 42, 1173-1178.	0.3	24
216	IDDM and rainfall. Lancet, The, 1993, 342, 1496.	6.3	0

#	Article	IF	CITATIONS
217	HLA-DQA1 and DQB1 gene polymorphisms in type I diabetic patients from central Italy and their use for risk prediction. Diabetes, 1993, 42, 1173-1178.	0.3	8
218	An Explanation for the Neutral Effect of DR2 on IDDM Susceptibility in Central Italy. Diabetes, 1992, 41, 904-908.	0.3	13
219	An explanation for the neutral effect of DR2 on IDDM susceptibility in central Italy. Diabetes, 1992, 41, 904-908.	0.3	4
220	The HLA system and insulin dependent diabetes: recent findings and prospects for disease prediction. Annali Di Igiene: Medicina Preventiva E Di Comunita, 1992, 4, 147-52.	0.5	0
221	Immunointervention in insulin dependent diabetes: implications for the epidemiology of the disease. Annali Di Igiene: Medicina Preventiva E Di Comunita, 1992, 4, 159-63.	0.5	0
222	Acute onset of seeming IDDM in an AIDS patient. Diabetes Care, 1992, 15, 1824-5.	4.3	3
223	Prevalence of serological markers for hepatitis-B in patients with insulin-dependent diabetes. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 1991, 8, 5-6.	0.2	0
224	A critical assessment of the interactions between the immune system and the hypothalamo-pituitary-adrenal axis. Journal of Endocrinology, 1989, 120, 183-187.	1.2	50
225	Expression of pro-opiomelanocortin gene and quantification of adrenocorticotropic hormone-like immunoreactivity in human normal peripheral mononuclear cells and lymphoid and myeloid malignancies Journal of Clinical Investigation, 1989, 83, 733-737.	3.9	115
226	Cushing's disease and prolonged spontaneous remission. Clinical case. Minerva Endocrinologica, 1989, 14, 137-41.	1.7	1
227	Thymopentin induces release of ACTH-like immunoreactivity by human lymphocytes. Journal of Clinical & Laboratory Immunology, 1989, 29, 157-9.	0.1	0
228	Effects of caloric restriction and exercise on B-Endorphin, ACTH and cortisol circulating levels in obesity. Physiology and Behavior, 1988, 42, 65-68.	1.0	20
229	Record Books and Patients With NIDDM: Waste of Time?. Diabetes Care, 1988, 11, 299-300.	4.3	0
230	Plasma Beta-Endorphin in Response to Oral Glucose Tolerance Test in Obese Patients. Hormone and Metabolic Research, 1987, 19, 204-207.	0.7	14
231	Hyperendorphinemia in obesity and relationships to affective state. Physiology and Behavior, 1986, 36, 937-940.	1.0	27
232	Immunoreactivities Against Different Tyrosine-Phosphatase 2 (IA-2)(256-760) Protein Domains Characterize Distinct Phenotypes in Subjects With LADA. Frontiers in Endocrinology, 0, 13, .	1.5	2